Matritech, Inc.

Companies sign distribution agreement for NMP22 Test Kit

Published in Elder Law Weekly, July 7th, 2004

Matritech, Inc., (MZT), a developer of protein-based diagnostic products for the early detection of cancer, and Wampole Laboratories, LLC, a wholly owned subsidiary of Inverness Medical Innovations, Inc., announced an agreement for the distribution of Matritech's NMP22 Test Kit.

Under the terms of the agreement, Wampole will receive exclusive rights to distribute the NMP22 ELISA (Enzyme Linked Immunosorbent Assay) Test Kit to hospitals and clinical reference laboratories in the United States. Matritech's own sales force will continue to sell the NMP22 BladderChek Test directly to urologists in their offices.

"Wampole's proven ability to market and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Elder Law Weekly

Source: Elder Law Weekly (2004-07-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry